Zhang, Qing Yuan; Sun, Tao; Yin, Yong Mei; Li, Hui Ping; Yan, Min; Tong, Zhong Sheng; Oppermann, Christina P.; Liu, Yun Peng; Costa, Romulo; Hegg, Roberto 
Source: Therapeutic advances in medical oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, MULHERES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHANG, Qing Yuan et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study. Therapeutic advances in medical oncology, v. 12, 2020Tradução . . Disponível em: https://doi.org/10.1177/1758835920963925. Acesso em: 18 nov. 2024.APA
Zhang, Q. Y., Sun, T., Yin, Y. M., Li, H. P., Yan, M., Tong, Z. S., et al. (2020). MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study. Therapeutic advances in medical oncology, 12. doi:10.1177/1758835920963925NLM
Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Hegg R. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study [Internet]. Therapeutic advances in medical oncology. 2020 ; 12[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/1758835920963925Vancouver
Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Hegg R. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study [Internet]. Therapeutic advances in medical oncology. 2020 ; 12[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/1758835920963925
